Vita Therapeutics is a company formed in 2018 out of Johns Hopkins that has a patented cell-based therapy that has shown impressive pre-clinical curative results in muscular dystrophy. Using induced pluripotent stem cells (iPSCs), we have derived human satellite cells, which have shown the ability to sustainably repair and replace muscle over time. This therapy also has the potential to positively impact all degenerative muscular diseases, chemotherapy-induced cachexia, and geriatric conditions. The company is currently preparing an IND (Investigational New Drug Application) for its lead therapy with the FDA and plans to submit in 2022.
MSCRF is helping Vita Therapeutics greatly by funding pre-clinical studies that will help the company better understand the proper dose to use for patients when they move into the clinic.